UNICA IRIS Institutional Research Information System

FANTINI, MASSIMO CLAUDIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 67.384
NA - Nord America 8.119
AS - Asia 3.745
SA - Sud America 932
Continente sconosciuto - Info sul continente non disponibili 450
AF - Africa 100
OC - Oceania 24
Totale 80.754
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 66.080
US - Stati Uniti d'America 7.898
SG - Singapore 1.594
CN - Cina 1.009
BR - Brasile 724
VN - Vietnam 441
SE - Svezia 357
FI - Finlandia 260
HK - Hong Kong 174
FR - Francia 162
DE - Germania 148
GB - Regno Unito 141
IN - India 100
CA - Canada 90
BD - Bangladesh 79
AR - Argentina 70
NL - Olanda 46
MX - Messico 45
EC - Ecuador 41
IQ - Iraq 40
TR - Turchia 35
CO - Colombia 34
KR - Corea 34
PK - Pakistan 30
ZA - Sudafrica 29
ID - Indonesia 27
AT - Austria 26
JP - Giappone 26
UZ - Uzbekistan 25
AU - Australia 22
PL - Polonia 22
ES - Italia 18
EG - Egitto 17
MA - Marocco 17
JM - Giamaica 16
PY - Paraguay 16
SA - Arabia Saudita 15
UA - Ucraina 15
VE - Venezuela 15
PH - Filippine 14
IL - Israele 13
RU - Federazione Russa 13
CZ - Repubblica Ceca 12
KZ - Kazakistan 11
MY - Malesia 11
CR - Costa Rica 10
HN - Honduras 10
IE - Irlanda 10
CL - Cile 9
HU - Ungheria 9
JO - Giordania 9
PE - Perù 9
AZ - Azerbaigian 8
CH - Svizzera 8
DK - Danimarca 8
LB - Libano 8
NP - Nepal 8
TN - Tunisia 8
TT - Trinidad e Tobago 8
KE - Kenya 7
OM - Oman 7
DO - Repubblica Dominicana 6
EE - Estonia 6
GT - Guatemala 6
LT - Lituania 6
NI - Nicaragua 6
PR - Porto Rico 6
BG - Bulgaria 5
DZ - Algeria 5
GR - Grecia 5
KG - Kirghizistan 5
SV - El Salvador 5
UY - Uruguay 5
BB - Barbados 4
CW - ???statistics.table.value.countryCode.CW??? 4
ET - Etiopia 4
GP - Guadalupe 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
BO - Bolivia 3
GY - Guiana 3
IR - Iran 3
MD - Moldavia 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
BH - Bahrain 2
BS - Bahamas 2
FJ - Figi 2
GF - Guiana Francese 2
IS - Islanda 2
KW - Kuwait 2
LU - Lussemburgo 2
LV - Lettonia 2
QA - Qatar 2
SN - Senegal 2
UG - Uganda 2
AG - Antigua e Barbuda 1
Totale 80.286
Salva come PNG Salva come JPEG
Città #
Cagliari 62.085
Uta 3.531
Ashburn 950
Fairfield 883
Singapore 781
San Jose 508
Woodbridge 404
Seattle 386
Dallas 374
Boardman 343
Houston 332
Cambridge 318
Wilmington 300
Nyköping 253
Council Bluffs 246
Helsinki 228
Los Angeles 187
Santa Clara 183
Beijing 152
Ho Chi Minh City 140
Hong Kong 138
New York 113
Ann Arbor 108
Lauterbourg 105
Boston 100
Hanoi 85
Jacksonville 81
Hefei 69
Shanghai 68
Rome 62
Buffalo 61
São Paulo 61
Milan 51
Chandler 46
San Diego 46
Columbus 43
The Dalles 40
Dearborn 37
Hangzhou 36
Munich 36
Atlanta 35
Chicago 34
Dong Ket 32
Orem 32
Redwood City 31
Frankfurt am Main 30
Phoenix 30
Rio de Janeiro 30
London 29
Montreal 29
Seoul 28
Guangzhou 26
Amsterdam 22
Brooklyn 21
Tashkent 21
Tokyo 21
Denver 20
Nuremberg 20
San Francisco 20
Da Nang 19
North Bergen 19
Baghdad 17
Lappeenranta 17
Melbourne 17
Mountain View 17
Nanjing 17
Toronto 17
Haiphong 16
Philadelphia 16
Belo Horizonte 15
Chennai 15
Curitiba 15
Guayaquil 15
Mexico City 15
Tianjin 15
Vienna 15
Warsaw 15
Brasília 14
Johannesburg 14
Salt Lake City 14
Turku 14
Düsseldorf 13
Redondo Beach 13
Turin 13
Ankara 12
Naples 12
Biên Hòa 11
Las Vegas 11
Medellín 11
Norwalk 11
Poplar 11
Quito 11
Stockholm 11
Zhengzhou 11
Brno 10
Kingston 10
Miami 10
Wuhan 10
Asunción 9
Guarulhos 9
Totale 75.038
Salva come PNG Salva come JPEG
Nome #
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.160
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.158
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history 1.961
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.661
RORGT-expressing tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells 1.600
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.598
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.572
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.353
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.344
Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study 1.322
Multidimensional Impact of Mediterranean Diet on IBD Patients 1.316
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 1.275
Quercetin and its derivates as antiviral potentials: A comprehensive review 1.256
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 1.225
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.205
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases 1.143
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.106
Reciprocal regulation between Smad7 and Sirt1 in the gut 1.081
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide 1.067
The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation 1.048
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 1.039
Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence 1.023
Heligmosomoides polygyrus bakeri infection decreases Smad7 expression in intestinal CD4+ T cells, which allows TGF-b to induce IL-10–producing regulatory T cells that block colitis 1.014
Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down? 1.001
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 974
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 970
Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death 950
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth 901
A functional role for Smad7 in sustaining colon cancer cell growth and survival 898
Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation 894
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 884
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 865
Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis 764
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages 761
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 749
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 726
Immune system and gut microbiota senescence in elderly IBD patients 722
Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis 713
Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells 700
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression 683
Smad7 expression in T cells prevents colitis-associated cancer 656
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study 647
Reprogramming the immune system in IBD 639
The impact of translational research on gastroenterology 637
Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy 619
null 617
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies 594
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations 584
Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression 577
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer 574
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine 563
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study 560
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies 552
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 542
Intestinal inflammation and colorectal cancer: a double-edged sword? 534
Inhibitory Effect of Quercetin on Oxidative Endogen Enzymes: A Focus on Putative Binding Modes 528
Diagnostic delay in adult coeliac disease: An Italian multicentre study 521
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 520
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases 510
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6 508
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus 505
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via a p38 Map kinase-dependent induction of SOCS-3 503
Regulation of homeostasis and inflammation in the intestine 502
High resolution colonoscopy in live mice 497
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut 489
Drug insight: novel small molecules and drugs for immunosuppression 488
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase 485
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 483
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis 479
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid 479
IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes 475
New players in the cytokine orchestra of inflammatory bowel disease 467
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis 464
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation 463
Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis 452
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells 446
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa 442
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling 442
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 440
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy 439
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 433
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 432
IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 430
Regulation of gut inflammation and th17 cell response by interleukin-21 429
IL-21 comes of age as a regulator of effector T cells in the gut 425
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study 422
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease 417
Cytokines: from gut inflammation to colorectal cancer 415
Role of interleukin-21 in inflammation and allergy 412
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease 410
In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells 410
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 405
TGF-beta as a T cell regulator in colitis and colon cancer 403
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes 403
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells 400
Telemedicine and remote screening for COVID-19 in inflammatory bowel disease patients: results from the SoCOVID-19 survey 395
Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy 390
Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum 388
Exploring Asphodelus microcarpus as a source of xanthine oxidase inhibitors: Insights from in silico and in vitro studies 387
IL-6 signaling promotes tumor growth in colorectal cancer 387
Totale 74.797
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.332 0 0 0 0 479 473 250 494 442 691 871 632
2022/20239.989 797 1.203 1.202 524 662 1.418 640 939 577 649 811 567
2023/202412.823 522 435 373 894 1.421 2.156 2.253 819 617 811 1.347 1.175
2024/202525.121 5.286 6.813 3.029 3.188 1.712 1.709 2.055 105 394 334 230 266
2025/20269.397 455 283 988 1.174 579 652 2.559 483 628 826 543 227
2026/20272.344 218 499 518 1.095 14 0 0 0 0 0 0 0
Totale 80.754